Terms: = Prostate cancer AND PTPN11, CFC, Q06124, 5781, ENSG00000179295, SHP2, MGC14433, SHP-2, BPTP3, PTP-1D, SH-PTP3, NS1, SH-PTP2, PTP2C
38 results:
1. Tyrosine phosphatase
Chen X; Keller SJ; Hafner P; Alrawashdeh AY; Avery TY; Norona J; Zhou J; Ruess DA
Front Immunol; 2024; 15():1340726. PubMed ID: 38504984
[TBL] [Abstract] [Full Text] [Related]
2. Phase I Clinical Trial of prostate-Specific Membrane Antigen-Targeting
Suh M; Ryoo HG; Kang KW; Jeong JM; Jeong CW; Kwak C; Cheon GJ
Korean J Radiol; 2022 Sep; 23(9):911-920. PubMed ID: 35762185
[TBL] [Abstract] [Full Text] [Related]
3. Clinical considerations for the design of PROTACs in cancer.
Nieto-Jiménez C; Morafraile EC; Alonso-Moreno C; Ocaña A
Mol Cancer; 2022 Mar; 21(1):67. PubMed ID: 35249548
[TBL] [Abstract] [Full Text] [Related]
4. prostate biopsy and prostate cancer management in patients with haemophilia: The experience of French Haemophilia Treatment Centres.
Gautier P; Guillet B; Sigaud M; Claeyssens S; Volot FG; Chamouni P; Lienahrt A; Frotscher B; Fournel A; Castet S; Poumayou C; Gay V; Thuret R; Wibaut B; Biron-Andreani C
Haemophilia; 2022 May; 28(3):437-444. PubMed ID: 35201650
[TBL] [Abstract] [Full Text] [Related]
5. Yeppoonic acids A - D: 1,2,4-trisubstituted arene carboxylic acid co-metabolites of conglobatin from an Australian Streptomyces sp.
Lacey H; Chen R; Vuong D; Cowled MS; Lacey E; Rutledge PJ; Piggott AM
J Antibiot (Tokyo); 2022 Feb; 75(2):108-112. PubMed ID: 34880415
[TBL] [Abstract] [Full Text] [Related]
6. Ethacrynic acid inhibits STAT3 activity through the modulation of shp2 and PTP1B tyrosine phosphatases in DU145 prostate carcinoma cells.
Lee YJ; Song H; Yoon YJ; Park SJ; Kim SY; Cho Han D; Kwon BM
Biochem Pharmacol; 2020 May; 175():113920. PubMed ID: 32201212
[TBL] [Abstract] [Full Text] [Related]
7. Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples.
Toomey S; Carr A; Mezynski MJ; Elamin Y; Rafee S; Cremona M; Morgan C; Madden S; Abdul-Jalil KI; Gately K; Farrelly A; Kay EW; Kennedy S; O'Byrne K; Grogan L; Breathnach O; Morris PG; Eustace AJ; Fay J; Cummins R; O'Grady A; Kalachand R; O'Donovan N; Kelleher F; O'Reilly A; Doherty M; Crown J; Hennessy BT
J Transl Med; 2020 Feb; 18(1):99. PubMed ID: 32087721
[TBL] [Abstract] [Full Text] [Related]
8. Assessment of Out-of-Pocket Costs for Robotic cancer Surgery in US Adults.
Nabi J; Friedlander DF; Chen X; Cole AP; Hu JC; Kibel AS; Dasgupta P; Trinh QD
JAMA Netw Open; 2020 Jan; 3(1):e1919185. PubMed ID: 31940036
[TBL] [Abstract] [Full Text] [Related]
9. Decline in arylsulfatase B expression increases EGFR expression by inhibiting the protein-tyrosine phosphatase shp2 and activating JNK in prostate cells.
Bhattacharyya S; Feferman L; Han X; Ouyang Y; Zhang F; Linhardt RJ; Tobacman JK
J Biol Chem; 2018 Jul; 293(28):11076-11087. PubMed ID: 29794138
[TBL] [Abstract] [Full Text] [Related]
10. Geranylnaringenin (CG902) inhibits constitutive and inducible STAT3 activation through the activation of shp-2 tyrosine phosphatase.
Jin Y; Yoon YJ; Jeon YJ; Choi J; Lee YJ; Lee J; Choi S; Nash O; Han DC; Kwon BM
Biochem Pharmacol; 2017 Oct; 142():46-57. PubMed ID: 28666623
[TBL] [Abstract] [Full Text] [Related]
11. Cripto-1 promotes epithelial-mesenchymal transition in prostate cancer via Wnt/β-catenin signaling.
Liu Y; Qin Z; Yang K; Liu R; Xu Y
Oncol Rep; 2017 Mar; 37(3):1521-1528. PubMed ID: 28098905
[TBL] [Abstract] [Full Text] [Related]
12. shp2 promotes metastasis of prostate cancer by attenuating the PAR3/PAR6/aPKC polarity protein complex and enhancing epithelial-to-mesenchymal transition.
Zhang K; Zhao H; Ji Z; Zhang C; Zhou P; Wang L; Chen Q; Wang J; Zhang P; Chen Z; Zhu HH; Gao WQ
Oncogene; 2016 Mar; 35(10):1271-82. PubMed ID: 26050620
[TBL] [Abstract] [Full Text] [Related]
13. CRIPTO overexpression promotes mesenchymal differentiation in prostate carcinoma cells through parallel regulation of AKT and FGFR activities.
Terry S; El-Sayed IY; Destouches D; Maillé P; Nicolaiew N; Ploussard G; Semprez F; Pimpie C; Beltran H; Londono-Vallejo A; Allory Y; de la Taille A; Salomon DS; Vacherot F
Oncotarget; 2015 May; 6(14):11994-2008. PubMed ID: 25596738
[TBL] [Abstract] [Full Text] [Related]
14. Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity.
Toso A; Revandkar A; Di Mitri D; Guccini I; Proietti M; Sarti M; Pinton S; Zhang J; Kalathur M; Civenni G; Jarrossay D; Montani E; Marini C; Garcia-Escudero R; Scanziani E; Grassi F; Pandolfi PP; Catapano CV; Alimonti A
Cell Rep; 2014 Oct; 9(1):75-89. PubMed ID: 25263564
[TBL] [Abstract] [Full Text] [Related]
15. In vivo passage of human prostate cancer cells in mice results in stable gene expression changes affecting numerous cancer-associated biological processes.
Sivanathan L; Chow A; Wong A; Hoang VC; Emmenegger U
Prostate; 2014 May; 74(5):537-46. PubMed ID: 24435653
[TBL] [Abstract] [Full Text] [Related]
16. IGF-1R modulation of acute GH-induced STAT5 signaling: role of protein tyrosine phosphatase activity.
Gan Y; Zhang Y; Buckels A; Paterson AJ; Jiang J; Clemens TL; Zhang ZY; Du K; Chang Y; Frank SJ
Mol Endocrinol; 2013 Nov; 27(11):1969-79. PubMed ID: 24030252
[TBL] [Abstract] [Full Text] [Related]
17. Low expression of shp-2 is associated with less favorable prostate cancer outcomes.
Tassidis H; Brokken LJ; Jirström K; Bjartell A; Ulmert D; Härkönen P; Wingren AG
Tumour Biol; 2013 Apr; 34(2):637-42. PubMed ID: 23192641
[TBL] [Abstract] [Full Text] [Related]
18. CD49f is an efficient marker of monolayer- and spheroid colony-forming cells of the benign and malignant human prostate.
Yamamoto H; Masters JR; Dasgupta P; Chandra A; Popert R; Freeman A; Ahmed A
PLoS One; 2012; 7(10):e46979. PubMed ID: 23071686
[TBL] [Abstract] [Full Text] [Related]
19. Demethoxycurcumin modulates prostate cancer cell proliferation via AMPK-induced down-regulation of HSP70 and EGFR.
Hung CM; Su YH; Lin HY; Lin JN; Liu LC; Ho CT; Way TD
J Agric Food Chem; 2012 Aug; 60(34):8427-34. PubMed ID: 22849866
[TBL] [Abstract] [Full Text] [Related]
20. Role of Cripto-1 during epithelial-to-mesenchymal transition in development and cancer.
Rangel MC; Karasawa H; Castro NP; Nagaoka T; Salomon DS; Bianco C
Am J Pathol; 2012 Jun; 180(6):2188-200. PubMed ID: 22542493
[TBL] [Abstract] [Full Text] [Related]
[Next]
